Eloxx Pharmaceuticals Inc.
| NASDAQ: ELOX | Healthcare / Biotechnology / USA |
| 2.38 | +0.0100 | +0.42% | Vol 1.87K | 1Y Perf -5.20% |
| Apr 23rd, 2021 09:35 DELAYED |
| BID | 2.27 | ASK | 2.40 | ||
| Open | 2.38 | Previous Close | 2.41 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 4.50 | Analyst Rating | Moderate Buy 2.00 | |
| Potential % | 89.08 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 95.71M | Earnings Rating | Strong Buy | |
| Price Range Ratio 52W % | 5.59 | Earnings Date | 6th May 2021 |
Today's Price Range 2.382.38 | 52W Range 2.126.77 | 5 Year PE Ratio Range -2.00-0.9000 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.69% | ||
| 1 Month | -28.40% | ||
| 3 Months | -40.15% | ||
| 6 Months | -19.93% | ||
| 1 Year | -5.20% | ||
| 3 Years | -77.85% | ||
| 5 Years | -54.42% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -135.83 | |||
ROE last 12 Months | -139.27 | |||
ROA (5Y Avg) | -75.35 | |||
ROA last 12 Months | -76.28 | |||
ROC (5Y Avg) | -126.97 | |||
ROC last 12 Months | -87.95 | |||
Return on invested Capital Q | -22.94 | |||
Return on invested Capital Y | -90.26 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -3.00 | ||||
| 11.87 | ||||
| - | ||||
| - | ||||
| -7.50 | ||||
| -0.70 | ||||
| 11.87 | ||||
| 0.21 | ||||
| 108.81M | ||||
| Forward PE | -3.13 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.50 | ||||
| 2.60 | ||||
| 0.39 | ||||
| 1.18 | ||||
| -23.50 | ||||
| Leverage Ratio | 2.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.22 | -0.15 | 31.82 |
| Q03 2020 | -0.19 | -0.16 | 15.79 |
| Q02 2020 | -0.22 | -0.20 | 9.09 |
| Q01 2020 | -0.29 | -0.35 | -20.69 |
| Q04 2019 | -0.33 | -0.29 | 12.12 |
| Q03 2019 | -0.39 | -0.32 | 17.95 |
| Q02 2019 | -0.37 | -0.40 | -8.11 |
| Q01 2019 | -0.41 | -0.33 | 19.51 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.16 | 11.11 | Positive |
| 6/2021 QR | -0.18 | 10.00 | Positive |
| 12/2021 FY | -0.70 | 16.67 | Positive |
| 12/2022 FY | -0.81 | 19.00 | Positive |
| Next Report Date | 6th May 2021 |
| Estimated EPS Next Report | -0.16 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.87K |
| Shares Outstanding | 40.22M |
| Trades Count | 11 |
| Dollar Volume | 391.90K |
| Avg. Volume | 95.49K |
| Avg. Weekly Volume | 100.34K |
| Avg. Monthly Volume | 105.17K |
| Avg. Quarterly Volume | 101.01K |
Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) stock closed at 2.37 per share at the end of the most recent trading day (a -1.66% change compared to the prior day closing price) with a volume of 82.48K shares and market capitalization of 95.71M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 29 people. Eloxx Pharmaceuticals Inc. CEO is Gregory Williams.
The one-year performance of Eloxx Pharmaceuticals Inc. stock is -5.2%, while year-to-date (YTD) performance is -40.45%. ELOX stock has a five-year performance of -54.42%. Its 52-week range is between 2.12 and 6.77, which gives ELOX stock a 52-week price range ratio of 5.59%
Eloxx Pharmaceuticals Inc. currently has a PE ratio of -3.00, a price-to-book (PB) ratio of 11.87, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -76.28%, a ROC of -87.95% and a ROE of -139.27%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Eloxx Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.16 for the next earnings report. Eloxx Pharmaceuticals Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Eloxx Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $4.5, which is +89.08% compared to the current price. The earnings rating for Eloxx Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Eloxx Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Eloxx Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.77, ATR14 : 0.36, CCI20 : -114.43, Chaikin Money Flow : -0.14, MACD : -0.42, Money Flow Index : 15.48, ROC : -25.00, RSI : 36.36, STOCH (14,3) : 18.94, STOCH RSI : 0.32, UO : 37.59, Williams %R : -81.06), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Eloxx Pharmaceuticals Inc. in the last 12-months were: Gregory Williams (Option Excercise at a value of $0), Neil S. Belloff (Option Excercise at a value of $0)
Eloxx Pharmaceuticals Inc.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel ribonucleic acid (RNA)-modulating drug candidates that are formulated to treat rare and ultra-rare premature stop codon diseases. The ELX-02, the company's lead investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins. The ELX-02, is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis.
CEO: Gregory Williams
Telephone: +1 781 577-5300
Address: 950 Winter Street, Waltham 02451, MA, US
Number of employees: 29
